Dayvigo (Lemborexant) and Sexual Function: What Women Need to Know

Why Sleep and Sexual Function Are Linked in Women Specifically

Poor sleep and low libido are not coincidentally connected. They share overlapping neurobiology, and this matters far more for women than is often acknowledged in prescribing discussions.

Research published in the Journal of Sexual Medicine found that each additional hour of sleep a woman got was associated with a 14% increase in the likelihood of sexual activity the following day. That finding came from a sample of premenopausal women, but the principle extends across life stages. Sleep debt suppresses testosterone in women as well as men, and testosterone is a meaningful driver of female desire even at the lower concentrations women carry.

The Orexin System and Female Desire

Orexin (also called hypocretin) is a neuropeptide produced in the hypothalamus that promotes wakefulness and also modulates arousal, mood, and reward circuits. The orexin system does not operate in isolation from sex hormones.

Animal data published in Neuropeptides show orexin-A neurons project into regions governing sexual behavior, and estrogen receptors are co-expressed in many of those same hypothalamic nuclei. This means the orexin system is not hormonally neutral in women. What this implies clinically is that a drug selectively blocking orexin signaling at night, rather than broadly sedating the brain, may carry a meaningfully different sexual-function profile compared to agents like zolpidem, quetiapine, or diphenhydramine.

How Chronic Insomnia Itself Suppresses Sexual Function

Before attributing any sexual symptom to a medication, it is worth recognizing what untreated insomnia does on its own. Chronic insomnia in women is associated with elevated cortisol and reduced slow-wave sleep, both of which lower dehydroepiandrosterone (DHEA) and free testosterone. A 2021 analysis in Sleep Medicine Reviews documented that women with insomnia disorder reported significantly worse sexual satisfaction scores than age-matched good sleepers, independent of depression or relationship status.

Treating the insomnia may therefore restore, not diminish, sexual function, and the mechanism by which a drug achieves sleep matters for whether that restoration actually happens.

How Lemborexant Works and Why the Mechanism Matters for Sexual Function

Lemborexant is a dual orexin receptor antagonist. It blocks both OX1R and OX2R, the two receptor subtypes through which orexin promotes wakefulness. By quieting the wake-promoting signal rather than activating inhibitory GABA pathways, lemborexant allows sleep to emerge through the brain's own architecture.

This is a fundamentally different pharmacology from benzodiazepines and Z-drugs (zolpidem, eszopiclone, zaleplon), which enhance GABAergic inhibition broadly. Broad GABA enhancement reduces limbic reactivity, which is one reason benzodiazepines are associated with blunted sexual response and delayed orgasm in both sexes.

The SUNRISE-1 trial, published in JAMA Network Open in 2019, randomized 291 adults with insomnia disorder to lemborexant 5 mg, lemborexant 10 mg, or zolpidem extended-release 6.25 mg. The trial was not powered to detect sexual function differences, but it demonstrated that next-morning subjective alertness and performance on a driving simulation task were meaningfully better with lemborexant 10 mg than with zolpidem ER. That preservation of morning cognitive and motor function is the indirect pathway most relevant to sexual wellbeing.

What SUNRISE-1 Found on Next-Day Functioning

In SUNRISE-1, participants on lemborexant 10 mg showed statistically superior next-morning alertness on a visual analog scale compared to zolpidem ER. The trial ran over 30 nights. Residual sedation is one of the clearest pharmacological mechanisms by which a sleep drug can impair sexual function, because morning and daytime grogginess reduces energy, motivation, and spontaneous desire.

Zolpidem has been reported in case series and one small crossover study to produce sexual side effects including reduced lubrication and delayed orgasm, effects attributed to its GABA-potentiating action. No equivalent case series exists for lemborexant as of mid-2025.

Receptor Selectivity and CNS Side-Effect Profile

Because lemborexant does not touch histamine, serotonin, or dopamine receptors at therapeutic doses, it avoids several mechanisms by which other sleep agents cause sexual dysfunction. Antihistamines reduce vaginal lubrication. Serotonin-heavy agents delay orgasm. Dopamine suppression blunts reward and desire. Lemborexant's relatively narrow receptor footprint is a genuine pharmacological advantage, not marketing language.

Clinical Trial Data on Sexual Function: What Exists and What Does Not

Here is where the evidence gap requires honest acknowledgment. No phase 2, phase 3, or post-marketing trial of lemborexant has used a validated female sexual function instrument, such as the Female Sexual Function Index (FSFI) or the Female Sexual Distress Scale (FSDS), as a primary or secondary endpoint.

This absence reflects a persistent pattern in insomnia drug development. Sexual function is rarely collected prospectively in sleep trials despite the biological logic connecting sleep quality to libido, arousal, and orgasm. The clinical inference that lemborexant preserves or improves sexual function in women rests on three pillars:

1. Mechanism (orexin-selective, no direct dopamine or serotonin effects)
2. Next-morning alertness data from SUNRISE-1 (indirect pathway)
3. The absence of sexual dysfunction in the adverse-event reporting from the phase 2 and phase 3 programs

The FDA prescribing information for lemborexant does not list decreased libido, anorgasmia, or sexual dysfunction among adverse reactions occurring in more than 1% of participants. That is reassuring but not equivalent to a prospective finding of no effect.

The SUNRISE-2 Trial: Longer-Term Data

SUNRISE-2 (published in Sleep, 2020) extended lemborexant evaluation to 12 months in 949 adults and reported that the drug maintained sleep efficacy without dose escalation. Again, sexual function was not formally assessed. But the 12-month safety data showed no new adverse event signals emerging over time, and the rate of CNS-related adverse events was comparable to placebo for most categories.

Women made up roughly 65% of the SUNRISE-2 population, which is noteworthy because insomnia is more prevalent in women. That enrollment composition at least means the safety data are not entirely male-derived, even if sex-stratified sexual function data were not reported.

Sexual Function Across Women's Life Stages: How Lemborexant Fits

Reproductive Years (Ages 18-40)

Women in their reproductive years with insomnia disorder are often caught between inadequate treatment (because providers hesitate to prescribe anything that might affect fertility or a future pregnancy) and undertreated sleep deprivation that quietly erodes mood, energy, and sexual desire.

Lemborexant does not appear to affect the hypothalamic-pituitary-ovarian axis based on available data, and it carries no known risk of menstrual cycle disruption. A woman on lemborexant who is sexually active and not seeking pregnancy needs reliable contraception, not because lemborexant is confirmed teratogenic but because animal studies showed developmental effects and human safety in pregnancy has not been established (see the pregnancy section below).

For women in this group experiencing hypoactive sexual desire that co-occurs with insomnia, treating the sleep disorder with a mechanistically clean agent is a reasonable first step before attributing the low desire entirely to psychological or relational factors.

Perimenopause (Approximately Ages 40-55)

This is the life stage where the lemborexant-sexual-function conversation is most clinically meaningful. Up to 60% of perimenopausal women report insomnia symptoms, and the overlap with sexual dysfunction in this group is substantial. The North American Menopause Society (NAMS) has noted that disturbed sleep in perimenopause is driven by vasomotor symptoms, shifting estrogen and progesterone levels, and rising hypothalamic noradrenergic tone, all of which also suppress desire and arousal independently.

A perimenopausal woman taking lemborexant who continues to experience low desire after her sleep improves should be evaluated for genitourinary syndrome of menopause (GSM), hypoactive sexual desire disorder (HSDD), and declining estrogen affecting vaginal tissue, not simply given a higher dose of her sleep medication.

The Menopause Society 2023 position statement on menopause hormone therapy supports the use of systemic estrogen for vasomotor symptoms and notes that improved sleep is one of the documented benefits of hormone therapy in this group. In a woman whose insomnia is primarily driven by hot flashes and night sweats, hormone therapy may address both sleep and sexual symptoms simultaneously, making lemborexant an adjunct rather than a standalone.

Post-Menopause

In post-menopausal women, the orexin system is altered. Research in Menopause has documented changes in hypothalamic neuropeptide signaling after estrogen withdrawal, including in the regions governing wake and sleep transitions. Whether orexin receptor antagonism produces the same clinical effect in a post-menopausal brain as in a pre-menopausal one is not yet known. The SUNRISE trials did not report sex-hormone-stratified subgroup analyses.

For post-menopausal women on concurrent hormone therapy, there is no identified pharmacokinetic interaction between estrogen formulations and lemborexant based on available data. Estradiol is metabolized predominantly via CYP3A4, and lemborexant is also a CYP3A4 substrate, so clinicians should use caution when adding potent CYP3A4 inhibitors (azole antifungals, clarithromycin) to the regimen of a woman on both lemborexant and estrogen.

PCOS

Women with polycystic ovary syndrome (PCOS) have a disproportionately high rate of sleep-disordered breathing and insomnia. A meta-analysis in Human Reproduction Update found that PCOS is associated with a 6-fold increase in odds of obstructive sleep apnea. Sleep fragmentation from any cause suppresses DHEA-S and free testosterone in women with PCOS just as it does in the general female population.

Lemborexant is not a first-line treatment for the insomnia of sleep apnea, and prescribing a sleep-consolidating agent in a woman with undiagnosed or untreated apnea carries risk of masking daytime consequences without addressing the underlying condition. A women with PCOS and insomnia should have sleep apnea excluded or treated before lemborexant is started.

Pregnancy, Lactation, and Contraception

This section is mandatory reading if you are pregnant, trying to conceive, or breastfeeding.

Pregnancy

Lemborexant is not assigned a traditional FDA letter category under the pre-2015 system, because it was approved under the newer 2015 FDA labeling rule requiring narrative descriptions rather than letter grades. The FDA prescribing label states that in rat studies, lemborexant at exposures above the maximum recommended human dose caused increased embryofetal mortality, reduced fetal body weight, and skeletal anomalies. No adequate and well-controlled human pregnancy studies exist.

Lemborexant should not be used during pregnancy. If you become pregnant while taking lemborexant, stop the medication and contact your prescriber promptly.

Because the drug is a Schedule IV controlled substance with no established safety in human pregnancy, women of reproductive potential who are taking lemborexant should use effective contraception. No specific contraceptive class is required by the label, and lemborexant does not appear to interact with combined oral contraceptives at a pharmacokinetic level, but this area has not been studied in a dedicated drug-drug interaction trial.

Lactation

Lemborexant transfer into human breast milk has not been studied. Based on molecular weight and lipophilicity, some transfer is pharmacologically plausible. The FDA label states that because of the potential for sedation in a breastfed infant, lemborexant is not recommended for use in women who are breastfeeding.

Postpartum insomnia is common and often undertreated because providers are cautious about any CNS-active agent during lactation. If you are breastfeeding and experiencing significant insomnia, cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment by AASM guidelines and carries no lactation risk. Lemborexant is not an appropriate substitute for CBT-I in a breastfeeding woman.

Trying to Conceive

No human fertility data exist for lemborexant. Animal reproductive toxicology at high doses showed implantation failure in rats. If you are actively trying to conceive, discuss this with your prescriber before starting or continuing lemborexant.

Who This Is Right For and Who Should Look Elsewhere

Women Who May Benefit Most

• Perimenopausal women with insomnia that is not fully explained by vasomotor symptoms, who have already optimized CBT-I and want pharmacotherapy with low next-day sedation burden
• Reproductive-age women with chronic insomnia disorder (not situational sleeplessness) who are using reliable contraception and whose low libido is likely sleep-related
• Post-menopausal women who have tried Z-drugs and experienced next-morning grogginess or who are concerned about the cognitive side effects of older sedatives
• Women with PCOS-related insomnia after sleep apnea has been evaluated and addressed

Women Who Should Use Caution or Choose Differently

• Women who are pregnant or breastfeeding (not appropriate)
• Women with untreated obstructive sleep apnea (lemborexant does not treat apnea and may mask daytime symptoms)
• Women taking strong CYP3A4 inhibitors (the dose should be reduced to 5 mg per night; see FDA label)
• Women with a history of parasomnias, as orexin antagonists as a class have been associated with sleep paralysis and hypnagogic hallucinations, though these rates were low in SUNRISE trials (approximately 1.5% at the 10 mg dose)
• Women with severe hepatic impairment (lemborexant is not recommended per label)

Comparing Lemborexant to Other Options Women Are Often Prescribed

Many women are offered options that carry documented sexual function liabilities. A brief comparison is worth making explicit:

Zolpidem (Ambien): Half of zolpidem prescriptions in the U.S. Go to women. The FDA reduced the recommended starting dose for women to 5 mg in 2013 after pharmacokinetic data showed women clear zolpidem 40-45% more slowly than men, leading to higher morning blood levels. That residual drug burden is the mechanism most likely to suppress morning energy, arousal, and initiation of sexual activity. Lemborexant does not show the same sex-based pharmacokinetic disparity.

Quetiapine: Frequently prescribed off-label for sleep in women with mood disorders. It carries prolactin elevation risk, and hyperprolactinemia is a direct suppressant of libido and lubrication. Lemborexant does not affect dopamine D2 receptors.

Diphenhydramine (Benadryl, Unisom): Anticholinergic activity reduces vaginal lubrication and can cause arousal difficulty. No such mechanism exists with lemborexant.

Suvorexant (Belsomra): The other approved DORA. A head-to-head trial published in Sleep Medicine showed lemborexant 10 mg achieved faster sleep onset and longer sleep maintenance than suvorexant 20 mg in adults with insomnia, with comparable tolerability. Sexual function was not assessed in that comparison either.

CBT-I: Still the first-line treatment. A 2024 meta-analysis in The Lancet confirmed CBT-I is superior to pharmacotherapy for long-term insomnia outcomes and should be offered before or alongside any sleep medication.

Practical Guidance: Getting the Most Out of Lemborexant Without Compromising Sexual Health

Take lemborexant only when you have at least seven hours available for sleep. Taking it with less than seven hours of sleep time planned is the single most likely way to create next-morning sedation that will spill over into your desire and energy the following day.

The starting dose is 5 mg. The 10 mg dose is available for women who need greater sleep-maintenance benefit, but the risk of sleep paralysis and next-morning effects is modestly higher at 10 mg than at 5 mg based on SUNRISE-1 data.

If you notice that your sexual desire worsens after starting lemborexant and your sleep is genuinely improving, the mechanism is unlikely to be the drug itself. Consider whether stress, relationship factors, androgen levels, or vaginal changes from hormonal shifts are the more likely explanation. A validated screening tool, the FSFI, takes under five minutes to complete and can give you a concrete baseline before and after starting any new sleep medication.

If you are in perimenopause and experiencing co-occurring hot flashes, night sweats, and low desire alongside insomnia, a conversation with a menopause-trained clinician about whether hormone therapy might address multiple symptoms simultaneously is worth having before you fill a lemborexant prescription.

The specific datum worth carrying into that conversation: the SWAN Sleep Study found that perimenopausal women reporting hot flashes had three times the rate of clinically significant insomnia as pre-menopausal women without vasomotor symptoms. Treating the underlying hormonal cause may reduce or eliminate the need for a chronic sleep medication.